Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Baseline characteristics400-IU group (n = 189) n(%)/mean(SD) n 1200-IU group (n = 209) n(%)/mean(SD) n p a Child Female sex90 (47.6)189100 (47.8)2090.96Gestational age, days280.5 (7.7)189281.4 (7.2)2090.23Parityb1.4 (0.6)1881.5 (0.7)2090.17Season of birth1892090.55Winter30 (15.9)40 (19.1)Spring75 (39.7)70 (33.5)Summer46 (24.3)58 (27.8)Autumn38 (20.1)41 (19.6) Mother Age31.64 (4.0)18931.44 (4.4)2090.63Non-smoking166 (88.8)187182 (88.8)205> 0.99BMI23.3 (3.7)18923.4 (3.7)2090.8225(OH)D83.6 (23.6)16183.9 (19.7)1730.90<50 nmol/L7 (4.3)7 (4.0)50 to 75 nmol/L54 (33.5)47 (27.2)>75 nmol/L101 (62.7)119 (68.8)aGroup differences calculated with t-test or χ2: testSD = Standard Deviation, BMI = body mass index, 25(OH)D = 25-hydroxyvitamin D, bnumber of siblings

Source: Characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Early life vitamin D and neurocognitive abilities at age 6 to 8 years: a randomized clinical trial and observational analysis

Source: Article title.

VIDI is a double-blind, randomized clinical trial studying vitamin D intervention in healthy term-born children [].

Source: Methods.

NEPSY-II is a neuropsychological test battery for children aged 3 to 16 years validated in Finnish population with Finnish norms [].

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Early life vitamin D and neurocognitive abilities at age 6 to 8 years: a randomized clinical trial and observational analysis

Multiple reported designs · European Child & Adolescent Psychiatry · 2025

Original publication title

Early life vitamin D and neurocognitive abilities at age 6 to 8 years: a randomized clinical trial and observational analysis

Vilja Seppälä; Samuel Sandboge; Elisa Holmlund-Suila; Helena Hauta-alus; Sakari Lintula; Eero Kajantie; Outi Mäkitie; Sture Andersson; Katri Räikkönen; Kati Heinonen

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Vitamin D is suggested to impact neurodevelopment, yet the current evidence is conflicting. We tested if vitamin D3 supplementation during the first two years of life, maternal 25-hydroxy-vitamin D (25(OH)D) concentration during pregnancy, and child’s 25(OH)D concentrations at 12 and 24 months are associated with neurocognitive abilities in 6.6-8.9-year-old children. Participants were from a Finnish vitamin D double-blind randomized clinical trial and classified themselves white. Children received either vitamin D3 400-IU (n = 189) or 1200-IU (n = 209) daily until 24 months of age.

Serum 25(OH)D was analyzed from mothers at mean of 11.2 weeks of gestation, and from children at 12.0 and 23.9 months (25(OH)D, mean (SD) = 83.8 (21.7), 102.3 (30.1), 105.5 (28.6) nmol/L, respectively). Total Intelligence quotient (IQ) score was assessed with Wechsler Intelligence Scale for Children (WISC-IV) and executive functioning with A Developmental Neuropsychological Assessment (NEPSY-II) and parent-rated Behavior Rating Inventory of Executive Function (BRIEF) questionnaire. Neurocognitive abilities at age 6 to 8 years did not differ between the supplementation groups or according to 25(OH)D concentration at 12 or 24 months (total IQ: β = 1.14, 95% CI -1.69;3.97, p = 0.43, executive functioning, NEPSY-II: β =-0.07, 95% CI -0.14;0.28, p = 0.49, executive functioning, BRIEF: β =-0.42, 95% CI -5.13;4.28, p = 0.86).

Maternal 25(OH)D was not associated with executive functioning. However, both lower and higher maternal 25(OH)D concentrations during pregnancy were associated with child’s lower total IQ scores (vertex at 76.6 nmol/L, quadratic estimate p < 0.001) supporting the hypothesis of the role of vitamin D during fetal development. The study is registered with ClinicalTrials.gov (NCT01723852, 2012-11-07 and NCT04302987, 2020-03-06).

Supplementary Information

The online version contains supplementary material available at 10.1007/s00787-025-02891-7.

Authors’ abstract

Vitamin D is suggested to impact neurodevelopment, yet the current evidence is conflicting. We tested if vitamin D3 supplementation during the first two years of life, maternal 25-hydroxy-vitamin D (25(OH)D) concentration during pregnancy, and child’s 25(OH)D concentrations at 12 and 24 months are associated with neurocognitive abilities in 6.6-8.9-year-old children. Participants were from a Finnish vitamin D double-blind randomized clinical trial and classified themselves white. Children received either vitamin D3 400-IU (n = 189) or 1200-IU (n = 209) daily until 24 months of age.

Serum 25(OH)D was analyzed from mothers at mean of 11.2 weeks of gestation, and from children at 12.0 and 23.9 months (25(OH)D, mean (SD) = 83.8 (21.7), 102.3 (30.1), 105.5 (28.6) nmol/L, respectively). Total Intelligence quotient (IQ) score was assessed with Wechsler Intelligence Scale for Children (WISC-IV) and executive functioning with A Developmental Neuropsychological Assessment (NEPSY-II) and parent-rated Behavior Rating Inventory of Executive Function (BRIEF) questionnaire. Neurocognitive abilities at age 6 to 8 years did not differ between the supplementation groups or according to 25(OH)D concentration at 12 or 24 months (total IQ: β = 1.14, 95% CI -1.69;3.97, p = 0.43, executive functioning, NEPSY-II: β =-0.07, 95% CI -0.14;0.28, p = 0.49, executive functioning, BRIEF: β =-0.42, 95% CI -5.13;4.28, p = 0.86).

Maternal 25(OH)D was not associated with executive functioning. However, both lower and higher maternal 25(OH)D concentrations during pregnancy were associated with child’s lower total IQ scores (vertex at 76.6 nmol/L, quadratic estimate p < 0.001) supporting the hypothesis of the role of vitamin D during fetal development. The study is registered with ClinicalTrials.gov (NCT01723852, 2012-11-07 and NCT04302987, 2020-03-06).

Supplementary Information

The online version contains supplementary material available at 10.1007/s00787-025-02891-7.

Publication and source details

Original title: Early life vitamin D and neurocognitive abilities at age 6 to 8 years: a randomized clinical trial and observational analysis

Vilja Seppälä; Samuel Sandboge; Elisa Holmlund-Suila; Helena Hauta-alus; Sakari Lintula; Eero Kajantie; Outi Mäkitie; Sture Andersson; Katri Räikkönen; Kati Heinonen

European Child & Adolescent Psychiatry · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Tampere University (including Tampere University Hospital)

Open access funding provided by Tampere University (including Tampere University Hospital).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:16:32.063075+00:00

DOI: 10.1007/s00787-025-02891-7 · PMC12957056